We are live on ! Find out more
JA

JLB & Associates Portfolio holdings

AUM $748M
1-Year Est. Return 27.21%
This Fund
S&P 500
This Quarter Est. Return
+1.98%
1 Year Est. Return
+27.21%
3 Year Est. Return
+69.53%
5 Year Est. Return
+110.76%
10 Year Est. Return
–
AUM
$363M
AUM Growth
+$9.88M
Cap. Flow
+$7.65M
Cap. Flow %
2.11%
Top 10 Hldgs %
30.44%
Holding
74
New
3
Increased
41
Reduced
28
Closed
1

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$8.81M
2
DLX icon
Deluxe
DLX
+$1.07M
3
KDP icon
Keurig Dr Pepper
KDP
+$716K
4
AAPL icon
Apple
AAPL
+$620K
5
GILD icon
Gilead Sciences
GILD
+$556K

Top Sells

Rank Stock Value
1
CLB icon
Core Laboratories
CLB
+$1.18M
2
DHR icon
Danaher
DHR
+$961K
3
SYK icon
Stryker
SYK
+$133K
4
MSFT icon
Microsoft
MSFT
+$130K
5
MDT icon
Medtronic
MDT
+$117K

Sector Composition

Rank Sector Weight
1 Industrials 19.82%
2 Consumer Discretionary 19.18%
3 Healthcare 18.38%
4 Technology 17.43%
5 Consumer Staples 12.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MA icon
1
Mastercard
MA
$507B
$13.8M 3.81%
135,727
+735
+0.5% +$70.5K
MKC icon
2
McCormick & Company Non-Voting
MKC
$14B
$13M 3.58%
259,990
+3,720
+1% +$189K
TTC icon
3
Toro Company
TTC
$8.83B
$11.4M 3.14%
242,875
+5,899
+2% +$276K
AAPL icon
4
Apple
AAPL
$4.67T
$10.8M 2.96%
380,400
+23,440
+7% +$620K
BCR
5
DELISTED
CR Bard Inc.
BCR
$10.7M 2.94%
47,528
+826
+2% +$186K
ACN icon
6
Accenture
ACN
$114B
$10.5M 2.91%
86,288
-935
-1% -$106K
NEU icon
7
NewMarket
NEU
$8.14B
$10.3M 2.85%
24,057
+471
+2% +$200K
APH icon
8
Amphenol
APH
$204B
$10.2M 2.8%
1,250,776
-2,624
-0.2% -$19.9K
MSFT icon
9
Microsoft
MSFT
$3.71T
$10M 2.76%
173,692
-2,300
-1% -$130K
GILD icon
10
Gilead Sciences
GILD
$187B
$9.82M 2.71%
124,165
+6,842
+6% +$556K
ROST icon
11
Ross Stores
ROST
$73.7B
$9.8M 2.7%
152,466
-1,075
-0.7% -$66.1K
ORCL icon
12
Oracle
ORCL
$457B
$9.38M 2.59%
238,770
+726
+0.3% +$29.6K
SEIC icon
13
SEI Investments
SEIC
$13.2B
$9.09M 2.51%
199,322
+2,416
+1% +$113K
KDP icon
14
Keurig Dr Pepper
KDP
$44.3B
$8.77M 2.42%
96,092
+7,561
+9% +$716K
CPRT icon
15
Copart
CPRT
$31.2B
$8.76M 2.42%
1,308,720
+19,744
+2% +$126K
PEP icon
16
PepsiCo
PEP
$188B
$8.73M 2.41%
80,306
+2,270
+3% +$245K
AMGN icon
17
Amgen
AMGN
$236B
$8.69M 2.4%
+52,120
New +$8.81M
TJX icon
18
TJX Companies
TJX
$145B
$8.41M 2.32%
225,086
+7,534
+3% +$295K
GGG icon
19
Graco
GGG
$12.6B
$8.38M 2.31%
339,915
+14,646
+5% +$366K
ROL icon
20
Rollins
ROL
$17.3B
$8.29M 2.29%
637,202
-5,812
-0.9% -$74K
CTSH icon
21
Cognizant
CTSH
$28.1B
$8.18M 2.25%
171,348
+1,249
+0.7% +$71.1K
GPN icon
22
Global Payments
GPN
$24.5B
$8.04M 2.22%
104,699
+6,725
+7% +$507K
DLX icon
23
Deluxe
DLX
$1.11B
$7.4M 2.04%
110,814
+15,690
+16% +$1.07M
PKG icon
24
Packaging Corp of America
PKG
$21.1B
$7.26M 2%
89,311
+51
+0.1% +$3.9K
NKE icon
25
Nike
NKE
$57B
$7.16M 1.97%
135,919
+961
+0.7% +$54.3K
1
2 3

Similar funds

VCM
Virtue Capital Management Brentwood, Tennessee $749M AUM 40.13% 1-Year Est. Return
QI
Qtron Investments Boston, Massachusetts $750M AUM 44.01% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
BCM
Bienville Capital Management New York $750M AUM 2.59% 1-Year Est. Return
BG
BDF Gestion Paris, France $747M AUM 47.35% 1-Year Est. Return
PCM
Permanent Capital Management Chicago, Illinois $747M AUM 17.94% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

JLB & Associates's Q3 2016 Portfolio in Review

As of Q3 2016, JLB & Associates held 74 positions worth $363M, up 2.8% from $353M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

JLB & Associates's Q3 2016 filing shows 3 new, 41 increased, 28 reduced and 1 closed positions. Its largest new stake was Amgen: 52,120 shares worth $8.69M. The largest sale was Core Laboratories, an estimated $1.18M.

By sector, the portfolio is most concentrated in Industrials at 20% of assets, up from 19% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • JLB & Associates's largest Q3 2016 buy was Amgen: 52,120 shares worth $8.69M.
  • JLB & Associates added most to Deluxe in Q3 2016, an estimated $1.07M increase.
  • JLB & Associates's biggest Q3 2016 reduction was Core Laboratories, cutting an estimated $1.18M.
  • JLB & Associates's ten largest holdings make up 30% of its $363M portfolio in Q3 2016.
  • JLB & Associates opened 3 new positions and closed 1 in Q3 2016.
  • JLB & Associates's portfolio value rose 2.8% quarter-over-quarter to $363M.

Based on JLB & Associates's 13F filing for Q3 2016, filed 26 Oct 2016.